COVID-19 rapid guideline: cystic fibrosis NG170, NICE (updated 7th October 2020)
On 7 October 2020, we withdrew our recommendations on reducing or deprioritising cystic fibrosis registry data entry, limiting transplant services and deferring transition to adult services because these emergency measures are no longer needed.
Purpose of review The current review provides an overview of key psychological issues and challenges for the cystic fibrosis (CF) transmembrane conductance regulator (CFTR) modulator era of care. It discusses research from diagnosis and beyond, to patient-team communication with a particular focus on medical trials, adherence and living with CFTR modulators. Recent findings The impact of the diagnosis on parents is immense and the complexity of treatment now and in the future, are a challenge for both parents and teams. Communicating digitally is starting to become daily practice for many in CF care, with coronavirus ...
Dutch artificial intelligence (AI) software developer Thirona said it has exclusively...Read more on AuntMinnie.comRelated Reading: Thirona, Smart Reporting team up on COVID-19 software Free AI software can help triage COVID-19 on x-ray Thirona unveils AI software for COVID-19 analysis
The Veneto region is one of the most affected Italian regions by COVID-19. Chronic lung diseases, such as chronic obstructive pulmonary disease (COPD), may constitute a risk factor in COVID-19. Moreover, respi...
In conclusion, we suggest that cystic fibrosis mutation carriers are potential members of a certain vulnerable group and the detection of such mutations in the population might be vital for the prevention of SARS-CoV-2 virus, and more specifically to limit its serious complications. PMID: 33009727 [PubMed - as supplied by publisher]
DEAR MAYO CLINIC: My cousin has cystic fibrosis. After graduating from college last December, she moved across the country to take a new job. Now she lives with me. I have always been worried about her, but I am more concerned now that COVID-19 cases are rising in our area. Although I know coughing is common [...]
Although many physicians believed that cystic fibrosis patients would be hard-hit by COVID-19, that has not happened. How has this group managed the pandemic so well?Southern Medical Journal
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has disrupted clinical trials worldwide . This could delay the approval of new medicines and reduce access to investigational treatments via clinical trials. This particularly impacts patients with rare diseases such as cystic fibrosis (CF).
Publication date: Available online 16 September 2020Source: Respiratory Medicine Case ReportsAuthor(s): Alicia A. Mirza, Elika J. Rad, Paul K. Mohabir
Polarean Imaging, a company based in North Carolina, is pursuing regulatory approval for clinical use of its hyperpolarized gas MRI. The technology is intended to assist in diagnosing respiratory conditions, something that would be particularly usefu...
Authors: Chapman KD, Moffett KS PMID: 32885259 [PubMed - in process]